Evidence map›Paper›PMID 42723803›Full record

ReviewTranslational lung cancer research2026

NRG1 fusions in non-small cell lung cancer: biology, diagnostics, and emerging HER2/HER3 therapies-a narrative review.

Andrea Marini, Irene Stasi, Antonio Pellino, Enrico Sammarco, Azzurra Farnesi, Cecilia Barbara, Ermelinda De Maio, Samanta Cupini, Gianna Musettini, Giulia Acconci and 10 more

Abstract readReview
In one paragraph

Review in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Andrea MariniDivision of Medical Oncology, Livorno Hospital, Azienda USL Toscana Nord Ovest, Livorno, Italy.ORCID https://orcid.org/0000-0001-9977-381X
Irene StasiDivision of Medical Oncology, Livorno Hospital, Azienda USL Toscana Nord Ovest, Livorno, Italy.
Antonio PellinoDivision of Medical Oncology, Livorno Hospital, Azienda USL Toscana Nord Ovest, Livorno, Italy.
Enrico SammarcoDivision of Medical Oncology, Livorno Hospital, Azienda USL Toscana Nord Ovest, Livorno, Italy.
Azzurra FarnesiDivision of Medical Oncology, Livorno Hospital, Azienda USL Toscana Nord Ovest, Livorno, Italy.
Cecilia BarbaraDivision of Medical Oncology, Livorno Hospital, Azienda USL Toscana Nord Ovest, Livorno, Italy.
Ermelinda De MaioDivision of Medical Oncology, Livorno Hospital, Azienda USL Toscana Nord Ovest, Livorno, Italy.
Samanta CupiniDivision of Medical Oncology, Livorno Hospital, Azienda USL Toscana Nord Ovest, Livorno, Italy.
Gianna MusettiniDivision of Medical Oncology, Livorno Hospital, Azienda USL Toscana Nord Ovest, Livorno, Italy.
Giulia AcconciDivision of Medical Oncology, Livorno Hospital, Azienda USL Toscana Nord Ovest, Livorno, Italy.
Linda BartaliniDivision of Medical Oncology, Livorno Hospital, Azienda USL Toscana Nord Ovest, Livorno, Italy.
Luna Chiara MasiniDivision of Medical Oncology, Livorno Hospital, Azienda USL Toscana Nord Ovest, Livorno, Italy.
Giulia SoriaDivision of Medical Oncology, Livorno Hospital, Azienda USL Toscana Nord Ovest, Livorno, Italy.
Elena SartoriDivision of Medical Oncology, Livorno Hospital, Azienda USL Toscana Nord Ovest, Livorno, Italy.
Ylenia NodariDivision of Medical Oncology, Livorno Hospital, Azienda USL Toscana Nord Ovest, Livorno, Italy.
Carmelo SpinellaDivision of Medical Oncology, Livorno Hospital, Azienda USL Toscana Nord Ovest, Livorno, Italy.
Luigi ColtelliDivision of Medical Oncology, Pontedera Hospital, Azienda USL Toscana Nord Ovest, Pontedera, Italy.
Adele ServadioDivision of Pathology, Livorno Hospital, Azienda USL Toscana Nord Ovest, Livorno, Italy.
Andrea GiustiDepartment of Molecular Pathology, Versilia Hospital, Azienda USL Toscana Nord Ovest, Viareggio, Italy.
Giacomo AllegriniDivision of Medical Oncology, Livorno Hospital, Azienda USL Toscana Nord Ovest, Livorno, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objective: Methods: A structured literature search was conducted in PubMed and major oncology conference databases. The primary search was performed in February 2026 and subsequently updated through May 15, 2026, during manuscript revision. English-language studies focusing on biological mechanisms, clinicopathological features, diagnostic strategies, and therapeutic approaches in Key Content and Findings: Conclusions:

Indexed as

HER3non-small cell lung cancer (NSCLC)NRG1 fusiontargeted therapyzenocutuzumab

Identifiers

PMID42723803
PMCPMC13557890

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.